Literature DB >> 18500778

Characterization of impurities in the bulk drug lisinopril by liquid chromatography/ion trap spectrometry.

Pei-xi Zhu1, Dan-hua Wang, Cui-rong Sun, Zhi-quan Shen.   

Abstract

Two trace impurities in the bulk drug lisinopril were detected by means of high-performance liquid chromatography coupled with mass spectrometry (HPLC/MS) with a simple and sensitive method suitable for HPLC/MSn analysis. The fragmentation behavior of lisinopril and the impurities was investigated, and two unknown impurities were elucidated as 2-(6-amino-1-(1-carboxyethylamino)-1-oxohexan-2-ylamino)-4-phenylbutanoic acid and 6-amino-2-(1-carboxy-3-phenylpro-pylamino)-hexanoic acid on the basis of the multi-stage mass spectrometry and exact mass evidence. The proposed structures of the two unknown impurities were further confirmed by nuclear magnetic resonance (NMR) experiments after preparative isolation.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18500778      PMCID： PMC2367377          DOI： 10.1631/jzus.B0820031

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN： 1673-1581            Impact factor:   3.066


  12 in total

Review 1.  LC/MS applications in drug development.

Authors:  M S Lee; E H Kerns
Journal:  Mass Spectrom Rev       Date:  1999 May-Aug       Impact factor: 10.946

2.  Mass spectral fragmentation reactions of angiotensin-converting enzyme (ACE) inhibitors.

Authors:  David J Burinsky; Scott L Sides
Journal:  J Am Soc Mass Spectrom       Date:  2004-09       Impact factor: 3.109

3.  Characterization of a novel trace-level impurity in lisinopril using multi-stage mass spectrometry.

Authors:  Saifeng Pei; Danhua Wang; Cuirong Sun; Yuanjiang Pan
Journal:  Eur J Mass Spectrom (Chichester)       Date:  2006       Impact factor: 1.067

4.  Characterization of a novel impurity in bulk drug of lisinopril by multidimensional NMR technique.

Authors:  Dan-hua Wang; Sai-feng Pei; Ming-hua Zhou; Cui-rong Sun; Yuan-jiang Pan
Journal:  J Zhejiang Univ Sci B       Date:  2006-04       Impact factor: 3.066

5.  Quantitative determination of the angiotensin-converting enzyme inhibitor lisinopril in human plasma by stable isotope dilution gas chromatography/negative ion chemical ionization mass spectrometry.

Authors:  H J Leis; G Fauler; G Raspotnig; W Windischhofer
Journal:  Rapid Commun Mass Spectrom       Date:  1998       Impact factor: 2.419

6.  Proposal for a common nomenclature for sequence ions in mass spectra of peptides.

Authors:  P Roepstorff; J Fohlman
Journal:  Biomed Mass Spectrom       Date:  1984-11

7.  Identification of a new impurity in lisinopril.

Authors:  Vikas Shinde; Anurag Trivedi; P R Upadhayay; N L Gupta; D G Kanase; Rajeev Chikate
Journal:  J Pharm Biomed Anal       Date:  2006-08-22       Impact factor: 3.935

8.  Development and validation of a stability indicating HPLC method for determination of lisinopril, lisinopril degradation product and parabens in the lisinopril extemporaneous formulation.

Authors:  Christopher A Beasley; Jessica Shaw; Zack Zhao; Robert A Reed
Journal:  J Pharm Biomed Anal       Date:  2004-12-16       Impact factor: 3.935

9.  Determination of the angiotensin-converting enzyme inhibitor lisinopril in urine using solid-phase extraction and reversed-phase high-performance liquid chromatography.

Authors:  Y C Wong; B G Charles
Journal:  J Chromatogr B Biomed Appl       Date:  1995-11-17

10.  A study of b1+H2O and b1-ions in the product ion spectra of dipeptides containing N-terminal basic amino acid residues.

Authors:  Richard D Hiserodt; Sharon M Brown; Dennis F H Swijter; Nicole Hawkins; Cynthia J Mussinan
Journal:  J Am Soc Mass Spectrom       Date:  2007-04-29       Impact factor: 3.109
View more
  1 in total

1.  Synthesis and Characterization of Compounds Related to Lisinopril.

Authors:  Ambati V Raghava Reddy; Srinivas Garaga; Chandiran Takshinamoorthy; Andra Naidu; Ramesh Dandala
Journal:  Sci Pharm       Date:  2015-10-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.